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Purpose: The retinal degeneration (rd1) mouse undergoes a rapid loss of rod photoreceptors due to a defect in the cGMP-
phosphodiesterase gene. We have previously demonstrated that dopamine (DA) antagonists or DA depletion blocks
photoreceptor degeneration and that DA is necessary for photoreceptor degeneration in the rd1 mouse retinal organ culture
model. Antagonists for either D1- or D2-family DA receptors are protective in rd1 organ cultures.
Methods: To determine whether photoreceptor survival can be increased in vivo in the rd1 mouse, we used both a
pharmacological and a genetic approach. The pharmacological approach involved three techniques to administer 6-
hydroxydopamine (6-OHDA) in an attempt to deplete DA in postnatal mouse retina in vivo. As a genetic alternative, DA
receptor signaling was inactivated by crossbreeding rd1 mice to D1, D2, D4, and D5 knockout mice to create four lines
of double mutants.
Results: Pharmacological DA depletion was incomplete due to the limiting size of the postnatal mouse eye and the lethality
of systemic inhibition of DA signaling. In all four lines of double mutants, no increase in rod photoreceptor survival was
observed. To determine whether protection of rd1 photoreceptors by inhibition of dopaminergic signaling is a result of
conditions specific to the organ culture environment, we grew in vitro retinas from the four lines of double mutant mice
for four weeks. Again, no increase in photoreceptor survival was seen. Finally, three triple mutants were generated that
lacked two DA receptors (D1/D2; D1/D4; and D2/D4) on a rd1 background. In all three cases, rod photoreceptors were
not protected from degeneration.
Conclusions: The dramatic protection of rd1 rod photoreceptors by inhibition of DA signaling in organ culture has not
been reproduced in vivo by either a pharmacological approach, due to technical limitations, or by genetic manipulations.
The possible role of compensatory effects during retinal development in DA receptor deficient mice is considered.
Retinitis pigmentosa (RP) is a genetically heterogeneous
family of inherited degenerative diseases in the retina. In
recent  years,  considerable  progress  has  been  made  in
elucidating  the  disease  processes  and  their  underlying
molecular mechanisms, in large part due to availability of
animal models of the disease. The rd1 mouse is among the
first identified [1] and best-characterized animal models of RP
[2]. The defect is caused by a loss-of-function mutation in the
β-subunit of the rod photoreceptor cGMP-phosphodiesterase
gene (PDE6b) [3-5]. This results in rod photoreceptor cell
death that begins by postnatal day 10 (P10) and is completed
by P21, at which time only cone nuclei remain in the outer
nuclear layer [6,7]. Mutations in PDE6b account for 4%–5%
of  human  cases  of  RP  [8-10],  making  the  rd1  mouse  a
particularly relevant model of human disease.
Numerous approaches are under study for treatment of
photoreceptor  degeneration—ranging  from  transplantation
and  prosthetic  devices  to  stem  cells,  gene  transfer,  and
pharmacological intervention using trophic factors or anti-
Correspondence  to:  Judith  Mosinger  Ogilvie,  Department  of
Biology, Saint Louis University, 3507 Laclede Ave, St. Louis, MO,
63103;  Phone:  (314)  977-3965;  FAX:  (314)  977-3658;  email:
ogilviej@slu.edu
apoptotic agents [11]. The rd1 retinal organ culture has proven
to  be  a  reliable  tool  for  screening  exogenously  applied
compounds  for  their  protective  effects  on  photoreceptors
[12-14]. Retinas isolated at P2 and grown in vitro for four
weeks show photoreceptor degeneration comparable to that
seen in vivo [15]. We and others have shown that several
neurotrophic factors added in combination can significantly
protect rd1 rod photoreceptors in organ culture. Among these
factors are brain-derived neurotrophic factor and glial cell
line-derived neurotrophic factor, both of which are known to
enhance survival and development of dopaminergic neurons
in the central nervous system (CNS) [12,13]. In the vertebrate
retina, dopamine (DA) plays several neuromodulatory roles,
including regulation of circadian rhythms, mediation of the
transition from scotopic to photopic vision, and modulation
of trophic effects on retinal development and ocular growth
(reviewed in [16]). DA acts through two families of G-protein
coupled receptors: D1-family receptors (D1 and D5) stimulate
adenylyl cyclase activity, while D2-family receptors (D2, D3,
and D4) inhibit adenylyl cyclase.
We  have  previously  shown  that  inhibition  of  DA
signaling can block the degeneration of rod photoreceptors in
the rd1 retinal organ culture system for four weeks [17]. This
result was achieved either through depletion of DA with 6-
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2868hydroxydopamine (6-OHDA) or with antagonists to either
D1-  or  D2-family  receptors.  Replication  of  the  protective
effect of DA inhibition in vivo could lead to new therapeutic
approaches for retinal degeneration. Here we have used both
pharmacological  and  genetic  approaches  to  determine
whether the protective effects of DA inhibition can be attained
in vivo in the rd1 mouse retina.
METHODS
Animals: Knockout (KO) mice lacking the D1, D2, D4, or D5
DA receptors (DR) were obtained from Drs. David Grandy
(Vollum  Institute,  Oregon  Health  Sciences  University,
Portland,  OR),  John  Drago  (University  of  Melbourne,
Parkville,  VIC,  Australia),  and  David  Sibley  (Molecular
Neuropharmacology  Section,  National  Institute  on
Neurologic  Disorders  and  Stroke,  National  Institutes  of
Health, Bethesda, MD) [18-21]. All strains were on a congenic
C57B1/6 background and were viable and fertile. Each line
was crossbred with rd1 homozygous mice, also on a C57B1/6
background, to produce heterozygous rd1/DR KO F1 hybrids.
These mice were then sib-crossed to produce homozygous
rd1/DR KOs for each of the four receptor subtypes. For all
organ culture experiments, littermates were used from crosses
of double mutants to either DR−/− rd1/+ or DR+/− rd1/rd1
heterozygote  mice.  Genotypes  were  identified  by  PCR
amplification of tail DNA with REDExtract-N-Amp PCR Kit
(Sigma,  St.  Louis,  MO)  following  the  manufacturer’s
instructions. The primers that were used are described in Table
1. All animals were handled in accordance with institutional
guidelines and the National Institutes of Health Guidelines on
Laboratory Animal Welfare.
Histopathology: Histopathology was performed on four to six
animals from each mutant line [15]. Histopathology reagents
were  purchased  from  EMS  (Hatfield,  PA).  Animals  were
euthanized with 0.1 ml pentobarbital at P21. The eyes were
enucleated, the anterior segment removed, and the remaining
eyecup  was  fixed  in  2.5%  glutaraldehyde  and  2%
paraformaldehyde  in  0.1  M  phosphate  buffer  at  4  °C
overnight, rinsed on ice two times in 0.1M phosphate buffer
and two times in water for 10 min each, postfixed in 1%
OsO4 for 1 h, rinsed two times for 10 min in water, dehydrated
through a stepwise ethanol series from 50% to 100%, and
embedded in Epon-Araldite. One micron plastic sections were
cut on a Leica UC6 Ultramicrotome and stained with toluidine
blue.
Pharmacological studies: Intraocular (i.o.) injections were
performed  on  wild  type  and  rd1  mouse  pups  with  two
injections given either at P4 and P7 or at P6 and P13. Animals
were anesthetized with 75 mg ketamine/kg bodyweight and
15  mg  xylazine/kg  bodyweight  injected  intraperitoneally.
Their eyelids were gently separated with forceps, and a glass
micropipette  connected  to  a  Hamilton  microsyringe  was
inserted into the vitreous and visualized through the cornea.
Up to 15 μg each of 6-OHDA (Sigma) and pargyline (Sigma)
in 0.5 μl sterile saline was injected. For subcutaneous (s.c.)
injections,  200  mg  6-OHDA/kg  bodyweight  dissolved  in
sterile saline with 0.1% ascorbic acid was injected at the nape
of the neck daily between P2–14. For combination studies,
pups  received  s.c.  injections  of  300  mg  6-OHDA/kg
bodyweight with 0.1% ascorbic acid daily between P2–7,
except on P4, when 9 μg each of 6-OHDA and pargyline were
injected  i.o.  Eyecups  were  harvested  at  P14  or  21  and
processed  either  for   histopathology,  as   described  in  the
previous   paragraph,   or   for   tyrosine   hydroxylase   (TH)
immunohistochemistry. For immunostaining, eyecups were
fixed in 4% paraformaldehyde, rinsed in 0.1 M phosphate
buffer, cryoprotected in 30% sucrose at 4 °C overnight, and
frozen in Optimal Cutting Temperature Compound (EMS).
TABLE 1. PRIMER SEQUENCES USED FOR PCR AMPLIFICATION
                         Gene Primer (5′-3′)
rd1 F: TGACAATTACTCCTTTTCCCTCAGTCTG
R: GTAAACAGCAAGAGGCTTTATTGGGAAC
Reverse wt primer: TACCCACCCTTCCTAATTTTTCTCACGC
D1 F: CTGATTAGCGTAGCATGGACTTTGTC
R: TGGATGTGGAATGTGTGCGAG
Reverse wt primer: TGGTGGCTGGAAAACATCAGA
D2 F: TGATGACTGCGAATGTTGGTGTGC
R: AGGATTGGGAAGACAATAGCAG
Reverse wt primer: CGGAGCCAAGCTAACACTGCAGAG
D4 F: GCCCGGTTCTTTTTGTCAAG
Forward wt primer: CATGGACGTCATGCTGTGCA
R: CGGACGAGTAGACCACATAG
D5 F: ACTCTCTTAATCGTCTGGACCTTG
R: GTTCAGATCCGCCGTATCTCCTCC
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with 1:200 goat anti-TH (Santa Cruz Biotechnology, Santa
Cruz, CA) in 5% normal donkey serum, 0.3% TritonX in PBS
(80  mM  Na2HPO4,  20  mM  NaH PO4,  100  mM  NaCl),
followed  by  1:200  donkey  anti-goat  Cy3  (Jackson
ImmunoResearch,  West  Grove,  PA)  for  1  h  at  room
temperature.
Organ culture: Retinas from double mutant mice were grown
in organ culture as previously described in detail [15]. Briefly,
P2  mouse  pups  were  anesthetized  on  ice,  eyes  were
enucleated, incubated in Dulbecco’s modified Eagle’s media
(DMEM;  #11965;  Gibco,  Rockville,  MD)  plus  0.05%
proteinase K (Invitrogen, Carlesbad CA) for 7 min at 37 °C,
rinsed  first  in  DMEM  with  10%  fetal  calf  serum  (FCS;
Summit  Biotechnology,  Ft.  Collins,  CO)  and  1.25  μg/ml
fungizone (Sigma) and then in the same media without FCS.
The sclera, choroid, and anterior segment were removed using
two pair of #5 forceps. The retina was separated from the
retinal  pigment  epithelia  during  a  30  min  incubation  in
DMEM with 10% FCS and 1.25 μg/ml fungizone at 37 °C.
Each retina was then transferred onto a Millipore Millicell-
CM culture insert (Millipore, Bedford, MA), photoreceptor
side down. Cultures were incubated in DMEM with 10% FCS
and 1.25 mg/ml fungizone. Cultures were maintained at 37 °C,
5% CO2, and fed every two to three days. Organ cultures were
harvested after 27 days in vitro, fixed in mixed aldehydes, and
processed  for  histology  as  described  in  Histopathology.
Pharmacologically  treated  organ  cultures  were  grown  as
previously  described  [17].  Two  treatment  protocols  were
used. Either 100 nM sulpiride (RBI Signaling, Natick, MA),
the D2-family receptor antagonist, was added to the media
daily  immediately  before  feeding,  or  a  combination  of
100 μM each 6-OHDA and pargyline were added to the media
on the first two days in culture with 50 μM each administered
on days 7 and 8.
Quantitative analysis: Quantitative analysis of photoreceptor
survival  was  performed  on  1  μm  sections  as  previously
described [15]. The thickness of the outer nuclear layer (ONL)
was  determined  by  an  observer  blinded  to  experimental
condition. The average number of ONL cells touching each
grid line on a reticule was counted in two regions on either
side of the midpoint for five columns each (total of ten counts).
An  ANOVA  statistical  test  was  used  to  determine
significance.
RESULTS
DA depletion is incomplete in the postnatal mouse retina in
vivo:  We  first  attempted  to  deplete  DA  by  adapting  well
established methods using 6-OHDA in the adult vertebrate
retina to the neonatal rd1 mouse [22,23]. Three approaches
were taken to modify this DA depletion technique to the small
eye of the postnatal mouse. First, we performed i.o. injections
of 6-OHDA. Second, we injected 6-OHDA s.c. daily for 12
days  beginning  at  P2.  Finally,  we  combined  these  two
methods with a single i.o. injection of 6-OHDA at P4 and s.c.
injections of 6-OHDA at all other days between P2–7. Stunted
growth  and  low  survival  rates  were  observed  in  animals
treated with the 12 day s.c. protocol. We saw no indication of
increased  photoreceptor  survival  in  retinas  harvested  for
histology at P21 with any of the protocols (data not shown).
To determine whether the DA depletion had been successful,
we processed retinas for immunohistochemistry and stained
them  with  antibodies  against  TH,  the  dopaminergic
biosynthetic enzyme. In all cases examined, we observed TH-
immunopositive cells in the treated retinas, indicating that the
administered dose of 6-OHDA was insufficient for depletion
of DA synthesis in the neonatal retina. Higher doses of 6-
OHDA injected s.c. as well as intraperitoneal injections were
lethal.  Higher  doses  of  6-OHDA  injected  i.o.  were  not
possible  due  to  the  small  size  of  the  postnatal  eye.  Thus
prospects  for  successful  DA  depletion  using  a
pharmacological approach seem poor in the postnatal in vivo
mouse retina.
DA receptor deletion does not protect rd1 photoreceptors in
vivo: We next used a genetic approach to block dopaminergic
signaling in the retina. Mice deficient in each of the four DA
receptor subtypes were crossed to rd1 mice to produce animals
homozygous  for  both  mutations.  These  four  DA  receptor
subtypes (D1, D2, D4, and D5) were selected for two reasons.
First, they are known to be expressed in the mammalian retina
[24]. Second, they are consistent with in vitro results using
pharmacological antagonists that can act on each of these
receptors. Eyecups were harvested at P21 for histopathology.
No increase in photoreceptor survival was observed in any of
the four double mutants (Figure 1). These results suggest that
the protective effects of DA receptor inhibition or depletion
in the organ culture cannot be replicated by deletion of a single
DA receptor in vivo.
DA receptor deletion does not protect rd1 photoreceptors in
vitro: To determine whether protection of rd1 photoreceptors
by  inhibition  of  dopaminergic  signaling  is  a  result  of
conditions  specific  to  the  organ  culture  environment,  we
harvested retinas from each of the double rd1/DR KO mutants
at P2 and allowed them to grow in organ culture for 28 days.
Retinas from age-matched siblings heterozygous for either the
DA  receptor  or  rd1  were  used  as  controls.  Photoreceptor
survival was not significantly increased in any of the four
double  mutant  retinas  examined  (Figure  2).  These  results
contraindicate the possibility that the increased photoreceptor
survival induced by DA depletion or DA receptor inhibition
is an artifact of the organ culture environment.
Multiple  DA  receptor  deletions  do  not  protect  rd1
photoreceptors in vivo: Because the protective effects of DA
antagonists  in  organ  culture  could  act  on  feedback  loops
involving multiple receptor subtypes, we created three triple
mutants by crossing DR KO mice lacking the most abundant
DA receptors in the retina, D1 and D2, with those lacking the
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2D4 receptor, which is the only family member demonstrated
to  be  expressed  in  mammalian  photoreceptors  [25].  D5
receptors were not included in this experiment since there is
no evidence to suggest they would play a significant role
independently of D1 receptors. No increased photoreceptor
survival was observed at P21 in animals with the following
three genotypes: (a) D1−/−, D2−/−, rd1/rd1; (b) D1−/−, D4−/−, rd1/
rd1; and (c) D2−/−, D4−/−, rd1/rd1 (Figure 3). These results
suggest that the failure of the genetic approach to recapitulate
the  protective  effects  of  DA  depletion  or  DA  receptor
inhibition seen in rd1 retinal organ culture is unlikely to result
from redundancy of DA signaling pathways in the KO mice.
To  test  the  possibility  that  an  alternative  signaling
pathway may be responsible for the protective effects of DA
inhibition previously observed in organ culture, we treated
organ cultures from D2−/−, D4−/−, rd1/rd1 triple mutant mice
either with the D2-family receptor antagonist, sulpiride, or
with the dopaminergic toxin, 6-OHDA. This triple mutant was
selected because it includes the only DA receptor known to
be expressed by photoreceptor cells and all related family
members known to be expressed in the retina. Although both
of these drugs produce complete protection of photoreceptors
in rd1/rd1 organ cultures, no protective effect was seen in the
absence of D2-family receptors (Figure 2G), providing further
evidence that DA acting through conventional dopaminergic
receptors is required for photoreceptor protection.
DISCUSSION
DA is an important neuromodulator throughout the CNS. It is
released from a very small subpopulation of interplexiform as
well as amacrine neurons in the retina that have recently been
demonstrated to display functional heterogeneity in both their
spontaneous  activity  and  light  responses  [26].  DA  acts
through  D1-  and  D2-receptor  families,  both  of  which  are
found in the inner and outer plexiform layers [27,28]. Only
the  D4  receptor  subtype  has  been  localized  to  rod
photoreceptors  [25,28,29],  with  expression  first  detected
Figure 1. Dopamine receptor deletion does not alter photoreceptor cell survival in rd1 retinas in vivo. Retinas from wild-type (A), rd1/rd1
(B), D1−/−, rd1/rd1 (C), D2−/−, rd1/rd1 (D), D4−/−, rd1/rd1 (E), and D5−/−, rd1/rd1 (F) mice were harvested at postnatal day 21. The ONL
of rd1/rd1 retinas was reduced to a monolayer of photoreceptors, regardless of DR genotype. Abbreviations: outer segments (OS); inner
segments (IS); outer nuclear layer (ONL); outer plexiform layer (OPL); inner nuclear layer (INL); inner plexiform layer (IPL); ganglion cell
layer (GCL). The scale bar represents 10 μm.
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2871around  birth  and  peaking  around  P12–14  [24,30].  In  the
mature retina, activation of the D4 receptor supports light
adaptation and inhibits the light-sensitive pool of cAMP in
photoreceptors [29,31,32]. D3 receptor expression has not
been detected in the vertebrate retina [24], while the role of
D5 receptors is poorly understood.
In a prior study using the four-week rd1 retinal organ
culture  model,  we  have  demonstrated  that  photoreceptor
degeneration is blocked by inhibition of DA signaling [17].
This  result  was  achieved  first  through  inhibition  of  DA
receptors with either D1- or D2-family receptor antagonists
(SCH-23390 and sulpiride, respectively). The finding that
antagonists  from  both  DA  receptor  families  could  block
photoreceptor degeneration was a robust result. This finding
is  consistent  with  synergistic  effects  of  D1-  and  D2-like
receptors in locomotor control [33-35]. In contrast, D1- and
D2-family receptors most often induce opposing responses in
the retina [16]. Photoreceptor protection was also achieved
through  DA  depletion  with  the  specific  dopaminergic
neurotoxin,  6-OHDA.  The  subsequent  readdition  of  the
broad-spectrum  DA  agonist  (±)-2-amino-6,7-
dihydroxy-1,2,3,4-tetrahydronapthalene  hydrobromide
(ADTN)  induced  photoreceptor  degeneration,  providing
powerful evidence that depletion of DA was the basis of the
protection afforded by 6-OHDA and that the antagonists were
acting  specifically  on  DA  receptors.  Here  we  report  that
Figure 2. Dopamine receptor deletion does not alter photoreceptor cell survival in rd1 retinal organ cultures. Retinas from D1−/−, rd1/+ (A),
D1+/−, rd1/rd1 (B), D1−/−, rd1/rd1 (C), D2−/−, rd1/rd1 (D), D4−/−, rd1/rd1 (E), and D5−/−, rd1/rd1 (F) mice were harvested at postnatal day
2 and grown in organ culture for 27 days in vitro. Wild-type retinas maintained approximately five to six rows of cells in the ONL (A), while
the ONL of untreated rd1/rd1 cultures, regardless of DR genotype, was reduced to approximately two to three rows (B-F). Quantitative analysis
of photoreceptor survival as measured by ONL thickness is shown in (G). Black bars represent the genotypes shown in A-F and additional
controls. Grey bars represent organ cultures from D2−/−, D4−/−, rd1/rd1 triple mutant mice treated with drugs as labeled. The number of
cultures is indicated on the column for each condition; error bars indicate standard deviation. No significant difference is seen in the ONL
thickness among rd1 organ cultures, regardless of DR genetic background or treatment. Similarly, no difference is seen among rd1 heterozygous
control organ cultures. Abbreviations: outer segments (OS); inner segments (IS); outer nuclear layer (ONL); outer plexiform layer (OPL);
inner nuclear layer (INL); inner plexiform layer (IPL); ganglion cell layer (GCL). The scale bar represents 10 μm.
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family  receptor  antagonist  sulpiride  provide  any
photoreceptor  protection  in  organ  cultures  from  rd1  mice
lacking both the D2 and D4 receptors. This finding provides
further  evidence  of  the  specificity  of  the  DA  signaling
pathway in photoreceptor protection in organ culture.
The protection observed in our prior study was striking
in that photoreceptor degeneration was completely blocked as
Figure 3. Deletion of multiple dopamine receptors does not alter photoreceptor cell survival in rd1 retinas in vivo. Retinas from D1−/−, D2−/
−, rd1/rd1 (A), D1−/−, D4−/−, rd1/rd1 (B), D2−/−, D4−/−, rd1/rd1 (C) mice were harvested at postnatal day 21. The ONL of rd1/rd1 retinas
was reduced to a monolayer of photoreceptors, regardless of DR genotype. Abbreviations: retinal pigment epithelium (RPE); outer nuclear
layer (ONL); outer plexiform layer (OPL); inner nuclear layer (INL); inner plexiform layer (IPL); ganglion cell layer (GCL). The scale bar
represents 10 μm.
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by  a  trained  observer;  the  observer,  who  was  blinded  to
experimental  condition,  was  unable  to  detect  any
morphological features to distinguish between wild type and
6-OHDA  treated  rd1  organ  cultures.  In  contrast,
photoreceptor  protection  by  the  growth  factor  ciliary
neurotrophic factor (CNTF) is due to negative regulation of
cell  differentiation,  a  distinction  that  is  apparent  in
heterochromatin staining [36,37].
In this study, we have applied several approaches in an
unsuccessful effort to reiterate the protective effects of DA
depletion in the rd1 mouse retina in vivo. Our first efforts to
administer  6-OHDA  through  intravitreal  as  well  as
subcutaneous routes were unsuccessful due to the limiting size
of the postnatal mouse eye and lethal effects of systemic
inhibition of DA signaling. Consistent with our results, mice
lacking both D1 and D2 receptors have been shown to survive
for no more than two to three weeks, most likely due to
decreased food intake and dysfunction of the gastrointestinal
system  [38].  Since  these  studies  were  unsuccessful  for
technical  reasons,  the  underlying  question  of  whether
pharmacological  inhibition  of  DA  signaling  might  be
protective for rd1 photoreceptors in vivo remains unanswered.
As an alternative, we used a genetic approach by crossing
mice lacking each of the four DA receptors expressed in the
retina  with  rd1  mice.  Again,  no  increased  photoreceptor
survival was seen in vivo. Furthermore, no photoreceptor
protection was observed in retinas from these double mutant
mice  grown  in  organ  culture.  Although  the  organ  culture
system recapitulates the photoreceptor degeneration of the
rd1 retina in vivo and has proven to be a useful tool for
investigating  protective  compounds  in  the  rd1  retina,  it
nevertheless differs from the in vivo retina. If the protective
effects of DA inhibition in the rd1 organ culture were due to
the  unique  characteristics  of  the  explant  system,  then  we
would expect to see increased photoreceptor survival in organ
cultures of DR KO retinas on an rd1 background. The fact that
this was not the case suggests that the protective effects of DA
signaling inhibition are not simply an artifact of the organ
culture system.
Finally, we considered the possibility that deletion of a
single DA receptor could be insufficient to mimic the effects
of DA antagonists that act on all members of a particular DA
receptor family. Our previous observation that both D1- and
D2-family  antagonists  could  block  photoreceptor
degeneration would be consistent with an interaction among
different types of DA receptors, possibly through a feedback
mechanism or heterodimerization. To test this possibility, we
bred triple mutant mice lacking two DA receptors (D1/D2;
D1/D4; and D2/D4) on a rd1 background. In all cases, no
protective  effect  was  observed.  In  light  of  these  negative
results, D5 double mutants were not tested. Since D5 receptors
have  no  known  effect  on  photoreceptors,  additional
experiments  seem  unlikely  to  produce  results  that  would
elucidate  our  findings.  Our  observations  with  the  double
mutant lines tested are consistent with a failure to detect a
compensatory increase of D2-like receptors in the nucleus
accumbens, caudoputamen and other striatal regions in D1
KO mice [18,39,40]. However, other compensatory effects
have been detected in DA receptor deficient mice as will be
discussed.
Efforts  to  understand  why  DA  inhibition  has  such  a
powerful protective effect in the organ culture model, yet has
not been demonstrated in vivo, is confounded by our poor
understanding  of  the  molecular  mechanisms  that  precede
photoreceptor cell death in the rd1 retina. The rd1 mouse
retina  is  a  well  characterized  animal  model  of  autosomal
recessive RP. A mutation in exon 7 of Pde6b results in a
nonfunctional  protein  and  leads  to  a  tenfold  increase  in
cytoplasmic  levels  of  cGMP  [2],  an  important  second
messenger signaling molecule in rod phototransduction. High
levels of Ca2+ have also been detected in the rd1 retina before
degeneration,  presumably  due  to  opening  of  cGMP-gated
cation channels [41,42].
Elevated cGMP is a feature of several models of RP in
various species, including cat, dog, and mouse [43-47], and
yet little is known about how cGMP induces cell death. Most
of these dystrophies belong to a subset of early onset retinal
degenerations. Pathology of the rd1 retina is consistent with
a  failure  of  rod  photoreceptors  to  undergo  normal  cell
differentiation.  Specifically,  rod  inner  segment  growth  is
stunted in the rd1 retina by P6 [48,49], and the photoreceptor
ribbon synapse fails to form the characteristic triad structure
[50]. Interestingly, PDE is expressed in developing retina by
embryonic day 12, much earlier than other genes that are
required for phototransduction [51]. Rhodopsin expression,
for  example,  is  first  detected  in  whole  retina  at  P5,
corresponding  with  growth  of  the  outer  segment  [51].
Together, these data suggest that regulation of cGMP levels
by PDE6 may play a role in photoreceptor differentiation
independent of its role in phototransduction in the mature
retina.
In  addition,  studies  indicate  that  DA  can  alter  cell
differentiation and neurite outgrowth during development of
the  vertebrate  retina  [52-55].  D1  and  D5  receptors,  in
particular, are expressed at high levels embryonically [24].
Similar observations have been made throughout the CNS
suggesting a significant role for DA in neuronal development
and differentiation [56-60]. These observations allow for the
possibility that genetic deletion of DRs in KO mice could lead
to modifications during embryonic retinal development that
may subsequently alter postnatal pathways that are essential
to the protective effects of DA inhibition observed in the
postnatal organ culture.
The failure of gene inactivation to mimic the effects of
antagonist drug administration has been observed in several
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attributed  to  compensatory  effects  that  take  place  during
development of the KO animal [61,62]. A striking example is
seen  in  locomotor  and  grooming  behaviors,  which  are
stimulated by D1 agonists and, paradoxically, enhanced in D1
receptor KO mice [63,64]. Similarly, locomotor activity is
strongly reduced by D2 antagonists, but significantly less of
an effect is seen in D2 receptor KO mice [65]. Interestingly,
D1- and D2-like receptor agonists act in a synergistic manner
to increase locomotor behavior even though they act through
different signaling pathways [33-35]. These results parallel
our observations that both D1- and D2-receptor antagonists
are protective of photoreceptors in rd1 retinal organ cultures,
but gene deletion fails to recapitulate this protection.
Other compensatory effects in DR KO mice have been
reported, such as altered levels of DA and its metabolites in
the midbrain of D1R and D2R KO mice [66,67]. Further
evidence  supports  genetic  interdependence  between  DA
receptors  and  other  neurotransmitter  receptors  including
adenosine  A2A  receptors  and  glutamatergic  N-methyl  D-
aspartate (NMDA) receptors [68-71]. For example, in the
D4R KO mouse, increased D1R and NMDA receptor binding
have  been  observed  in  both  the  nucleus  accumbens  and
caudate putamen, while only NMDA receptor binding was
increased in the hippocampus; no change was seen in D2R
binding [71]. Similarly, A2A receptor binding was increased
in several brain regions in both D1R and D2R KO mice [69].
Alterations in several neuromodulatory pathways, including
decreases in dynorphin and substance P expression, have been
demonstrated  in  D1R  KO  mouse  striatum  [18,40,72].
Together,  these  studies  and  others  point  to  the  complex,
pleiotrophic effects of gene inactivation and are consistent
with  the  existence  of  functional  interactions  among  these
signaling systems during development. Efforts to elucidate
these  effects  have  focused  on  making  conditional  and
inducible KO mice. The creation of inducible DR KO mice,
with gene inactivation triggered at the same developmental
age as used for the organ cultures (P2), would allow for further
investigation of developmental regulation due to loss of DA
receptor  function  during  terminal  photoreceptor  cell
differentiation.
In  conclusion,  the  dramatic  protection  of  rd1  rod
photoreceptors by inhibition of DA signaling in organ culture
has not been reproduced in vivo by either pharmacological or
genetic manipulations. Pharmacological efforts were limited
by the small size of the postnatal mouse eye combined with
lethal  effects  in  the  developing  animal.  Thus  technical
limitations have prevented inhibition of DA signaling in the
postnatal retina, leaving the question of potential therapeutic
relevance unanswered. The genetic approach, by comparison,
does block DA signaling through inactivation of each DA
receptor, but this approach is protective neither in vivo nor in
organ culture. Further studies are needed to determine whether
compensatory pathways that may alter cGMP signaling occur
during development in the DR KO mouse retinas.
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